SEC Filing Summary: AIKIDO PHARMA INC. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AIKIDO PHARMA INC. (not Dominari Holdings Inc.) on November 9, 2021, covering events that occurred on November 3, 2021. The registrant is a Delaware corporation with its principal executive offices in New York, NY, and its common stock trades on the NASDAQ Capital Market under the symbol AIKI.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is an amendment to the Company's Amended and Restated Bylaws, effective November 3, 2021:
- Quorum Requirement: The amendment allows holders of 33 1/3% of the outstanding shares of stock entitled to vote to constitute a quorum at a meeting of stockholders for the transaction of any business.
- Bylaws Title: The bylaws were renamed to the "Amended and Restated Bylaws of AIkido Pharma Inc." to reflect the Company's name change from March 2020.
- Other Changes: No other changes were made to the bylaws.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors beyond the standard incorporation by reference of the Amendment text. The document notes that the description of the Amendment is qualified in its entirety by reference to the complete text filed as Exhibit 3.1.
Key Facts for Investor Verification
- Verify the exact quorum threshold (33 1/3%) in the full text of the Amendment (Exhibit 3.1) to understand its impact on shareholder meeting dynamics.
- Confirm the Company's current legal name is AIKIDO PHARMA INC., as the filing corrects the bylaws title to match the 2020 name change.
- Note that this filing contains no financial performance data; investors should refer to the most recent 10-K or 10-Q for financial metrics.